Impact of Interleukin 28B and ICAM-1 Genetic Polymorphisms on Response to Direct Antiviral Treatment Among HCV Infected Patients

• Published in: Endocrine, metabolic & immune disorders drug targets Vol. 20; no. 8; p. 1328
• Main Authors: Elsheredy, Amel G, Almaeen, Abdulrahman H, Ghazy, Amany A, Helaly, Ghada F, Amer, Ibrahim, Ghazy, Haneen A, Haydara, Tamer
• Format: Journal Article
• Language: English
• Published: United Arab Emirates 01-01-2020
• Subjects: Adult; Antiviral Agents - therapeutic use; Case-Control Studies; Egypt - epidemiology; Female; Genotype; Hepatitis C - drug therapy; Hepatitis C - epidemiology; Hepatitis C - genetics; Humans; Intercellular Adhesion Molecule-1 - genetics; Interferons - genetics; Male; Middle Aged; Polymorphism, Single Nucleotide - genetics; Treatment Outcome; Egypt; direct antiviral agents; viral response; Hepatitis C virus; ICAM-1 single nucleotide polymorphism; IL-28B
• ISSN: 2212-3873
• DOI: 10.2174/1871530320666200505113619

Single nucleotide polymorphisms (SNPs) of IL-28B and/or ICAM-1 could have a role in expecting a response from HCV infected patients to direct antiviral agents (DAAs).
The aim of the current study was to investigate the impact of IL-28B rs12979860 and rs8099917, and, ICAM-1 rs281437 SNPs on response to treatment with sofosbuvir + Daclatsvir ± Ribavirin, among HCV-infected Egyptian patients.
Whole blood genomic DNA was extracted from 120 participants (80 HCV-infected patients and 40 healthy volunteers). HCV-infected patients were subdivided into responders and nonresponders to DAAs. Liver function testing, anti-HCV antibodies, HCV-RNA viral load and HCV genotyping were performed. IL-28B and ICAM-1 SNPs were evaluated by real-time PCR.
ALT and AST levels were significantly higher among non-responder HCV infected patients (P = 0.001*). 90% of the patients had HCV genotype 4a and the remaining 10% had 4l genotype. Allelic discrimination revealed that IL-28B rs12979860 T, IL-28B rs809917 T and ICAM-1 rs281437 C alleles were more frequent among HCV-infected patients (responders or non-responders) than controls. However, IL-28B rs8099917 G allele was more frequent among healthy controls. Regarding the response to DAAs treatment, HCV-infected patients with IL-28B rs8099917 GG genotype showed a significantly earlier viral response compared to those carrying TT alleles. ICAM-1 rs281437 CT alleles were non significantly more frequent among responders. However, IL-28B rs12979860 alleles did not show any difference.
Genotyping of IL-28B rs8099917 is a useful independent tool for expecting a response of Egyptian HCV-infected patients to DAAs.